Aehnlich Pia, Leuchte Katharina, Schöllkopf Claudia, Salo Sara Fresnillo, Seremet Tina J, Høgdall Estrid, Met Özcan, Grønbaek Kirsten, Straten Per Thor
Department of Oncology, National Center for Cancer Immune Therapy (CCIT-DK), Copenhagen University Hospital Herlev, Herlev, Denmark.
Department of Hematology, Copenhagen University Hospital, Copenhagen, Denmark.
Biomark Res. 2024 Dec 18;12(1):158. doi: 10.1186/s40364-024-00704-8.
The TAM receptor tyrosine kinase family member AXL plays critical roles in tissue homeostasis, survival, chemoresistance, and motility. This study investigates the receptor expression in six AML cell lines and bone marrow myeloblasts from 25 patients with myeloid neoplasms. We found that AXL expression was generally absent or very low in AML myeloblasts. These findings suggest that the efficacy of AXL inhibitors may not depend on AXL positivity but rather on alternative therapeutic mechanisms, such as inducing significant immune responses.
TAM受体酪氨酸激酶家族成员AXL在组织稳态、细胞存活、化疗耐药及细胞迁移中发挥关键作用。本研究调查了6种急性髓系白血病（AML）细胞系及25例髓系肿瘤患者骨髓成髓细胞中的该受体表达情况。我们发现，AML成髓细胞中通常不存在AXL表达或其表达水平极低。这些发现表明，AXL抑制剂的疗效可能不取决于AXL的阳性表达，而取决于其他治疗机制，如诱导显著的免疫反应。
